DOI: 10.1111/bju.16248 ISSN: 1464-4096

Added value of randomized biopsy to mpMRI‐targeted biopsy of the prostate in a contemporary cohort

Michael Chaloupka, Nikolaos Pyrgidis, Benedikt Ebner, Yannic Volz, Paulo L. Pfitzinger, Elena Berg, Benazir Enzinger, Michael Atzler, Troya Ivanova, Dirk‐André Clevert, Alexander Buchner, Christian G. Stief, Maria Apfelbeck
  • Urology


To assess the added value of concurrent systematic randomized ultrasound‐guided biopsy (SBx) to multiparametric magnetic resonance imaging (mpMRI)‐targeted biopsy and the additional rate of overdiagnosis of clinically insignificant prostate cancer (ciPCa) by SBx in a large contemporary, real‐world cohort.

More from our Archive